ArticleCancer science2022
Treatment patterns and survival in advanced unresectable esophageal squamous cell cancer: A population-based study.
Article in Cancer science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 3 syntheses or guidelines pooled it, 15 citations in OpenAlex.
- Cervical lymph node metastases in thoracic esophageal cancer: a systematic review.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2026Pooled it
- Does chemotherapy regimen matter for first-line immunochemotherapy in low PD-L1-expressing esophageal squamous cell carcinoma? A systemic review and meta-analysis.Esophagus : official journal of the Japan Esophageal Society · 2026Pooled it
- Tislelizumab efficacy and safety compared to other anti-PD-1s: a network meta-analysis of first-line therapies for unresectable, locally advanced or metastatic esophageal squamous cell carcinoma.Frontiers in immunology · 2025Pooled it
- The success of anti-PD-1 with chemotherapy for esophageal squamous cell carcinoma.Cell reports. Medicine · 2023Trial
- Overcoming chemoresistance in esophageal cancer with synergistic strategies.Frontiers in immunology · 2026Review
- Second-line oxaliplatin reintroduction or paclitaxel-ramucirumab in metastatic gastroesophageal cancer: a population-based study.Therapeutic advances in medical oncology · 2026Article
- Global burden of esophageal diseases: a comprehensive analysis of disease trends and risk factors from 1990 to 2021.BMC gastroenterology · 2025Article
- Considerations to forgo systemic treatment in patients with advanced esophageal or gastric cancer: A real-world evidence study.International journal of cancer · 2025Article
- Recognizing the Role for Conversion Therapy in Metastatic Esophageal Squamous Cell Cancer (ESCC): A Call for Future Study.Annals of surgical oncology · 2025Article
- Construction of a Novel Mitochondria-Associated Gene Model for Assessing ESCC Immune Microenvironment and Predicting Survival.Journal of microbiology and biotechnology · 2024Article
- Long-term health-related quality of life in patients with advanced esophagogastric cancer receiving first-line systemic therapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Observational
- DASES: a database of alternative splicing for esophageal squamous cell carcinoma.Frontiers in genetics · 2023Article
- A tricarboxylic acid cycle-based machine learning model to select effective drug targets for the treatment of esophageal squamous cell carcinoma.Frontiers in pharmacology · 2023Article
- Treatment patterns and survival in advanced unresectable esophageal squamous cell cancer: A population-based study.Cancer science · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
Abstract
Data on treatment and survival of patients with advanced unresectable esophageal squamous cell carcinoma (ESCC) from Western populations are limited. Here we describe treatment and survival in patients with advanced unresectable ESCC: patients with cT4b disease without metastases (cT4b), metastases limited to the supraclavicular lymph nodes (SCLNM) or distant metastatic ESCC at the population level. All patients with unresectable (cT4b) or synchronous metastatic ESCC at primary diagnosis (2015-2018) or patients with metachronous metastases after primary non-metastatic diagnosis in 2015-2016 were selected from the Netherlands Cancer Registry. Fifteen percent of patients had cT4b disease (n = 146), 12% SCLNM (n = 118) and 72% distant metastases (n = 681). Median overall survival (OS) time was 6.3, 11.2, and 4.4 months in patients with cT4b, SCLNM, and distant metastases, respectively (P < .001). Multivariable Cox regression showed that patients with cT4b (hazard ratio 1.44, 95% CI 1.04-1.99) and patients with distant metastases (hazard ratio 1.42, 95% CI 1.12-1.80) had a worse survival time compared with patients with SCLNM. Among patients who received chemoradiotherapy and/or underwent resection (primary tumor and/or metastases), median OS was 11.9, 16.1, and 14.0 months in patients with cT4b, SCLNM, and distant metastases, respectively (P = .76). Patients with SCLNM had a better survival time compared with patients with cT4b and patients with distant metastases. Survival of patients with advanced unresectable ESCC in clinical practice was poor, even in patients treated with curative intent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.